I was never a high risk patient so this would do absolutely no good for me. You'll have to ask your doctor is this might apply to you.
http://www.news-medical.net/news/20170330/Single-dose-of-siRNA-molecule-offers-protection-against-heart-attack-and-stroke-in-high-risk-patients.aspx
Even a single dose of a specific ribonucleic acid molecule, known as a
small interfering RNA (siRNA), offers patients at high risk of
cardiovascular disease long-lasting protection against high LDL
cholesterol - one of the main risk factors for heart attack and stroke.
This is the result of a clinical study that researchers from Charité and
Imperial College London have published as leading authors in the
current edition of New England Journal of Medicine.
As a component of cell walls and a building block of numerous
hormones, cholesterol plays an important role in the cell's lipid
metabolism. However, too much LDL cholesterol in the blood results in an
increased risk of atherosclerosis
(hardening of the arteries) and problems such as heart attack and
stroke. Patients suffering from a genetic disorder which causes very
high levels of LDL cholesterol are at a particularly high risk. In these
patients, a protein known as PCSK9 (proprotein convertase
subtilisin/kexin type 9) prevents the liver from removing LDL
cholesterol from the blood.
In
their study, Prof. Ulf Landmesser, Head of Charité's Department of
Cardiology (Campus Benjamin Franklin), and Prof. Kausik Ray from
Imperial College London, used the principle of RNA interference. The
process, which was discovered a few years ago, uses RNA molecules (small
interfering RNA) to inhibit the synthesis of harmful proteins. When
double-stranded siRNA is introduced into a cell, it will bind to a
molecule known as the RNA-induced silencing complex (RISC complex). This
allows the process to be used in a targeted manner to silence specific
genes.
In their study, the researchers investigated how effective and
efficient a specific siRNA was at targeting the PCSK9 protein. A total
of 501 high-risk patients with high LDL cholesterol levels received
varying subcutaneous doses of either inclisiran or placebo. Results
showed that inclisiran led to a significant reduction in levels of both
the protein and LDL cholesterol, with LDL cholesterol levels being
reduced by up to 41.9 percent after a single dose, and up to 52.6
percent after two doses.
"It was particularly interesting to see just how sustained the effect
of treatment was, with the effect of a single dose remaining apparent
for a duration of over nine months," explains Prof. Ulf Landmesser. He
adds: "The next step will be to further develop this treatment by
conducting a large clinical outcome trial. We are hoping to test what
might become a new type of therapy for the prevention of heart attack
and stroke in high-risk patients."
No comments:
Post a Comment